{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T03:56:28Z","timestamp":1773546988771,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.taap.2023.116628","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T11:53:11Z","timestamp":1690372391000},"page":"116628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["CD19 chimeric antigen receptor T cell therapy in leukemia xenograft mouse: Anti-leukemic efficacy, kinetics, and 4-week single-dose toxicity"],"prefix":"10.1016","volume":"475","author":[{"given":"Joo-Il","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi-Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Euna","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyoung Jin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byeong-Cheol","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.taap.2023.116628_bb0005","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1671761","article-title":"In vivo generated human CAR T cells eradicate tumor cells","volume":"8","author":"Agarwal","year":"2019","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.taap.2023.116628_bb0010","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/gt.2015.4","article-title":"Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model","volume":"22","author":"Almasbak","year":"2015","journal-title":"Gene Ther."},{"issue":"177","key":"10.1016\/j.taap.2023.116628_bb0015","doi-asserted-by":"crossref","first-page":"177ra138","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"176","key":"10.1016\/j.taap.2023.116628_bb0020","doi-asserted-by":"crossref","first-page":"20201013","DOI":"10.1098\/rsif.2020.1013","article-title":"Quantifying the limits of CAR T-cell delivery in mice and men","volume":"18","author":"Brown","year":"2021","journal-title":"J. R. Soc. Interface"},{"issue":"26","key":"10.1016\/j.taap.2023.116628_bb0025","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.taap.2023.116628_bb0030","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.omtm.2018.11.010","article-title":"Development of a novel anti-CD19 chimeric antigen receptor: a paradigm for an affordable CAR T cell production at academic institutions","volume":"12","author":"Castella","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"224","key":"10.1016\/j.taap.2023.116628_bb0035","doi-asserted-by":"crossref","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.taap.2023.116628_bb0040","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.taap.2023.116628_bb0045","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","article-title":"Neurotoxicity associated with CD19-targeted CAR-T cell therapies","volume":"32","author":"Gust","year":"2018","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.taap.2023.116628_bb0050","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25502","article-title":"Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy","volume":"86","author":"Gust","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.taap.2023.116628_bb0055","doi-asserted-by":"crossref","first-page":"3425291","DOI":"10.1155\/2019\/3425291","article-title":"Efficiency of CAR-T therapy for treatment of solid tumor in clinical trials: a meta-analysis","volume":"2019","author":"Hou","year":"2019","journal-title":"Dis. Markers"},{"issue":"95","key":"10.1016\/j.taap.2023.116628_bb0060","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"23","key":"10.1016\/j.taap.2023.116628_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21239163","article-title":"Identification of potent CD19 scFv for CAR T cells through scFv screening with NK\/T-cell line","volume":"21","author":"Kang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.taap.2023.116628_bb0070","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/CCO.0000000000000668","article-title":"CD19-directed CAR T-cell therapy in B-cell NHL","volume":"32","author":"Kersten","year":"2020","journal-title":"Curr. Opin. Oncol."},{"issue":"1","key":"10.1016\/j.taap.2023.116628_bb0075","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/eji.201948205","article-title":"Rapid thymectomy of NSG mice to analyze the role of native and grafted thymi in humanized mice","volume":"50","author":"Khosravi-Maharlooei","year":"2020","journal-title":"Eur. J. Immunol."},{"issue":"16","key":"10.1016\/j.taap.2023.116628_bb0080","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.taap.2023.116628_bb0085","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"24","key":"10.1016\/j.taap.2023.116628_bb0090","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","article-title":"Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia","volume":"24","author":"Mueller","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.taap.2023.116628_bb0095","doi-asserted-by":"crossref","first-page":"E459","DOI":"10.1073\/pnas.1524155113","article-title":"Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies","volume":"113","author":"Rodgers","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.taap.2023.116628_bb0100","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1089\/hum.2017.243","article-title":"Preclinical models in chimeric antigen receptor-engineered T-cell therapy","volume":"29","author":"Siegler","year":"2018","journal-title":"Hum. Gene Ther."},{"issue":"4","key":"10.1016\/j.taap.2023.116628_bb0105","doi-asserted-by":"crossref","first-page":"234","DOI":"10.4274\/tjh.galenos.2020.2020.0070","article-title":"Preclinical assessment of efficacy and safety analysis of CAR-T cells (ISIKOK-19) targeting CD19-expressing B-cells for the first Turkish academic clinical trial with relapsed\/refractory ALL and NHL patients","volume":"37","author":"Tastan","year":"2020","journal-title":"Turk. J. Haematol."},{"issue":"23","key":"10.1016\/j.taap.2023.116628_bb0110","doi-asserted-by":"crossref","first-page":"735","DOI":"10.21037\/atm.2019.12.03","article-title":"Preclinical safety evaluation of chimeric antigen receptor-modified T cells against CD19 in NSG mice","volume":"7","author":"Wen","year":"2019","journal-title":"Ann. Transl. Med."},{"issue":"1","key":"10.1016\/j.taap.2023.116628_bb0115","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13045-018-0572-x","article-title":"A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia","volume":"11","author":"Weng","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.taap.2023.116628_bb0120","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.taap.2023.116628_bb0125","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12885-021-07934-1","article-title":"Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies","volume":"21","author":"Ying","year":"2021","journal-title":"BMC Cancer"},{"issue":"14","key":"10.1016\/j.taap.2023.116628_bb0130","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/bloodadvances.2018017004","article-title":"Sequential allogeneic and autologous CAR-T-cell therapy to treat an immune-compromised leukemic patient","volume":"2","author":"Zhang","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.taap.2023.116628_bb0135","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.omto.2020.06.016","article-title":"Efficacy and safety of CD28- or 4-1BB-based CD19 CAR-T cells in B cell acute lymphoblastic leukemia","volume":"18","author":"Zhao","year":"2020","journal-title":"Mol. Ther. Oncol."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X23002673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X23002673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:03:43Z","timestamp":1758575023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X23002673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":27,"alternative-id":["S0041008X23002673"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2023.116628","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD19 chimeric antigen receptor T cell therapy in leukemia xenograft mouse: Anti-leukemic efficacy, kinetics, and 4-week single-dose toxicity","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2023.116628","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116628"}}